How companies can preserve market dominance after patents expire

Long Range Planning

Volumn 39, Issue 1, 2006, Pages 71-87

  Pearce II, John A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPETITION; FINANCE; MARKETING; STRATEGIC PLANNING;

GENERIC PRODUCT; PATENT PROTECTION; PRE-EXPIRATION STRATEGY;

PATENTS AND INVENTIONS;

COMPETITION (ECONOMICS); INNOVATION; MARKET; PROFITABILITY;

EID: 33747256350     PISSN: 00246301     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lrp.2005.04.006     Document Type: Article

References (60)

1. Grabowski H.G., and Vernon J.M. Brand, loyalty, entry and price competition in pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics 35 2 (1992) 331-350 Research has found that the correlation between patents awarded and innovations delivered to market vary widely among industries. Pharmaceutical and chemical industries were found to have the strongest positive correlation
2. Mansfield E. Patents and Innovation: An Empirical Study. Management Science 32 2 (1986) 173-182
3. Despite theory, empirical research reveals that patents rarely confer perfect appropriability. Although patents are effective for protecting the competitive advantages of new technology in most chemical industries, including the drug industry, they are ineffective in most other industries. Additionally, patents on new products are seen as more effective than process patents. Levin R.C. A New Look at the Patent System. The American Economic Review 76 2 (1986) 199-203
4. The most prominent of these agreements are the World Trade Organisation agreement signed by 117 nations in 1995, The Paris Convention for the Protection of Industrial Property signed by 96 countries and the World Intellectual Property Organisation, an agency of the United Nations that administers 16 international intellectual property treaties.
5. Magnier M. US Gains in Effort to Protect Intellectual Property in Asia. Journal of Commerce February 3 (1992) 1-3
6. Global Software Piracy, Business Software Alliance, June 21, press release (1996).
7. D. Ranii, Generic drugs face legal hurdles, Tribune Business News, September 29 (2001).
8. Industry Profile 2002. PhRMA (2002).
9. A. M. Rouhi, Generic Tide is Rising, Chemical and Engineering News, September 23, 37-51 (2002).
10. Alpert B. Whose drugs?. Barron's 83 11 (2003) 26-28
11. Bae J.P. Drug patent expirations and the speed of generic entry. Health Services Research 32 1 (1997) 87-101
12. Industry Profile 2002. op cit at Ref 7.
13. L. Kowalczyk, Consumer Group sues over price of cancer drug, Boston Globe, May 10 (2001).
14. Rouhi, op cit at Ref 8.
15. Grabowski and Vernon, op cit at Ref 1.
16. Liang B.A. The anticompetitive nature of brand-name firm introduction of generics before patent expiration. Antitrust Bulletin 41 3 (1996) 599-635
17. C. Yang, The drugmakers vs. the trustbusters, Business Week, September 5, 67-68 (1994).
18. Gans J.S., Hsu D.H., and Stern S. When does start-up innovation spur the gale of creative destruction?. The Rand Journal of Economics 33 4 (2002) 571-587
19. Caves R.E., Whinston M.W., and Hurwitz M.A. Patent Expiration, Entry and Competition in the US Pharmaceutical Industry. Brookings Papers: Microeconomics (1991) l-47
20. Grabowski and Vernon, op cit at Ref 1.
21. Comanor W.S., and Schweitzer S.O. Pharmaceuticals. In: Adams W., and Brock J. (Eds). The Structure of American Industry (1995), Prentice-Hall, Englewood Cliffs, NJ 177-196
22. M. Ballon, Generic Drug Fight Gains Potency as Patents Expire, Los Angeles Times, June 10 (2001).
23. D. Shook, Forest Labs: Feeling No Pain, Business Week Online, March 24 (2003).
24. G. Groeller, With Claritin patent due to expire, drug maker hypes Clarinex, The Orlando Sentinel, May 20 (2002).
25. Alpert, op cit at Ref 9.
26. Findlay S., and Development D. JAMA 292 21 (2004) 2662-2664 Also, in 2003, the average cost of testing and marketing a new drug was approximately $900m, according to the Tufts Center for the Study of Drug Development which calculated the 2003 figures based on the dollars value in 2001. Overall, according to the Pharmaceutical Research and Manufacturers of America, drug companies invested $33bn 2003 in their drug development efforts
27. Goozner M. The $800 Million Pill: The Truth behind the Cost of New Drugs (2004), University of California Press, Berkeley
28. Mansfield E., Schwartz M., and Wagner S. Imitation Costs and Patents: An Empirical Study. The Economic Journal 91 364 (1981) 907-919
29. Richard C. Levin, Alvin K. Klevorick, Richard R. Nelson, Sidney G. Winter, Appropriating the Returns from Industrial Research and Development; Comments and Discussion, Brookings Papers on Economic Activity, Washington, 783-832 (1987).
30. M. Kanellos, Intel, AMD to trim prices for holidays, CNET News.com, October 24 (2003); J. Lyman, Intel's Pentium 4 Strategy Paves Way for 2GHz Version, NewsFactor Network, July 27 (2001).
31. Chip-industry veteran joins Xyron before product launch. The Business Journal of Portland (2002). http://www.bizjournals.com/portland/stories/2002/02/04/daily8.html
32. D. Forman, Fully Funded, Nanosys Pursues Initial Product Launch By 2006, Small Times, July 21 (2003).
33. I. M. Kunii and A. Reinhardt, Matsushita: Back to the Glory Days, Business Week, July 21 (2003).
34. Kamel E. From a Patent Supporter. Software Magazine 11 13 (1991) 8-10
35. The rewards for innovation versus imitation vary greatly among industries. Research has found that rewards are highest in pharmaceuticals; lower in chemicals, electronics and machinery industries; lower still in semiconductors. Mansfield, Schwartz and Wagner, op cit at Ref 26.
36. Davis R., Samuelson P., Kapor M., and Reichman J.H. A New View of Intellectual Property and Software. Communications of the ACM 39 3 (1996) 22-30
37. Castelluccio M. Give away the store and get rich, eProject.corn's online business plan. Strategic Finance 81 10 (2000) 59-62
38. Castelluccio M. Can The Enterprise Run on Free Software?. Strategic Finance 81 9 (2000) 50-55
39. J. Kerstetter, S. Hamm, S. E. Ante and J. Greene, The LINUX Uprising, Business Week, March 3 (2003).
40. R. Kerber, RSA Security to Release Software Code Early Firm Seeks to Reassure Investors as Patent Ends, Boston Globe, September 7 (2000).
41. Sixth Patent Granted for SupportSoft's Award-Winning Technology, PR Newswire, October 29 (2002).
42. Check Point Performance Innovation and Leadership Recognized with patent for SecureXL Technology, Business Wire, February 19 (2003).
43. Porter M.E., and Strategy C. (1980), Free Press, New York
44. Pearce II J.A. Selecting Among Alternative Grand Strategies. California Management Review 30 2 (1982) 23-31
45. Treacy M., and Wiersema F. Customer Intimacy and Other Value Disciplines. Harvard Business Review January (1993) 84-93
46. Examples of articles with a mid-range focus include. Yang D., Sonmez M., and Bosworth D. Intellectual Property Abuses: How should Multinationals Respond?. Long Range Planning 37 5 (2004) 459-475
47. Grand S., von Krogh G., Leonard D., and Swap W. Resource allocation beyond firm boundaries: A multi-level model for Open Source innovation. Long Range Planning 37 6 (2004) 591-610
48. Day G.S., and Schoemaker P.J.H. Driving Through the Fog: Managing at the Edge. Long Range Planning 37 2 (2004) 127-142
49. Pearce II J.A., and Robinson Jr. R.B. Hostile Takeover Defenses that Maximize Shareholder Wealth. Business Horizons 47 5 (2004) 15-24
50. Doh J.P., and Pearce II J.A. Corporate Entrepreneurship and Real Options in Transitional Policy Environments. Journal of Management Studies 41 4 (2004) 645-664
51. and. Pearce II J.A. Speed Merchants. Organizational Dynamics 30 3 (2002) 191-205
52. McGrath R.G., Tsai M.H., Venkataraman S., and MacMillian I.C. Innovation, Competitive Advantage, and Rent: A Model and Test. Management Science 42 3 (1996) 389-403
53. Clemens E., and Row M. Sustaining IT advantage: The Role of Structural Differences. Management Information Systems Quarterly 15 3 (1991) 25-35
54. Stata R. Management innovation. Executive Excellence 9 6 (1992) 8-9
55. Adams G.L., and Lamont B.T. Knowledge management systems and developing sustainable competitive advantage. Journal of Knowledge Management 7 2 (2003) 142-154
56. Ghemawat P. Sustainable advantage. Harvard Business Review 64 (1986) 53-58
57. Dickson P.R. Towards a general theory of competitive rationality. Journal of Marketing 56 1 (1992) 69-83
58. Teece D.J. Strategies for managing knowledge assets: the role of firm structure and individual context. Long Range Planning 33 (2000) 35-54
59. Amit R., and Shoemaker P.J. Strategic assets and organizational rent. Strategic Management Journal 14 (1993) 33-45
60. Kandampully J., and Duddy R. Competitive advantage through anticipation, innovation, and relationships. Management Decision 37 1 (1999) 51-56